source
- J&J's Halda-derived prostate cancer drug shows 75% response in early Phase 1 trialJohnson & Johnson's recent $3 billion purchase of Halda Therapeutics added an oral prostate cancer candidate, JNJ-6143, to its pipeline. The drug targets a cancer-specific protein to trigger cell d…
- Patient dies after receiving Bristol Myers experimental autoimmune CAR-T therapy zola-celA participant in Bristol Myers Squibb’s multiple sclerosis trial died 44 days after being infused with the experimental cell therapy known as zola-cel. The company disclosed that the patient develo…